Kaitlin Mara

Kaitlin Mara

NGOs, Industry Weigh Alternatives For R&D Financing, Counterfeiting At WHO

The past year’s expert working group process at the World Health Organization on solutions for financing of research and development into diseases afflicting poor nations was flawed and led to an unsatisfactory result, representatives of non-governmental organisations said this week. But innovation and access can both be provided, and the issue of IP protection can be de-linked from the way innovation is done, speakers at a side event to this week’s World Health Assembly said. Meanwhile, NGOs and industry also offered their views on WHO counterfeiting efforts this week.

WHO: No Evidence Of Misleading On Counterfeit Medicines

There is no evidence that the work of the World Health Organization has been misled or misled its members on the issue of fake or dangerous drugs, representatives of the UN organisation told journalists today. Nor is the WHO yet ready to drop use of the term 'counterfeit' to describe such medicines despite generic producing nations complaints about possible confusion over the term.

Proposals At WHO Would Boost Drug Safety, Replace Anti-Counterfeiting Taskforce

Discussion at the annual World Health Assembly on counterfeit medicines may prove lively as stakeholders continue to raise concerns that the term “counterfeit” will confuse protecting patients from unsafe drugs with protecting trademarks from infringement. And an industry-led event in the lead-up to the WHA said counterfeit medicines pose great risks and will require a coordinated international response.

Developing Countries Blast WHO Report On IP, Demand “Credible” Approach

A critical report on financing research and development of medicines for the world's poorest was created without transparency, failed to live up to its mandate, and did not address the potential threat that intellectual property rights can pose to access to drugs, developing countries said today at the World Health Assembly. A proposal by a group of Latin American countries for a new intergovernmental working group was not accepted by developed countries and others and quick informal consultations began to work out differences before the end of the assembly this week.

Chan Urges Innovation, Defends WHO Flu Response As New Group Approved

World Health Organization Director General Margaret Chan opened the annual World Health Assembly today with a welcome of the transparency in the “most closely watched pandemic in history,” and how the drive to meet the UN Millennium Development Goals would unleash a “host of innovations for improving health, especially among the poorest,” adding a call for vaccines as one of the “best life-saving buys on offer.”

WHO Members To Act On Research Financing, Pandemic Preparedness

How to proceed with the results of an initiative aimed at finding real alternatives for innovative health research financing is on the agenda at next week's World Health Assembly (WHA). The assembly also is expected to approve the continuation of a working group on pandemic influenza preparedness.

Counterfeit Medicines In WTO Dispute Process, Heating Up At WHO

The international policy debate over counterfeit medicines and legitimate generics escalated today. Brazil and India took the first step in the World Trade Organization dispute settlement process for treatment of generics medicines falsely labelled counterfeit in Europe, and non-governmental organisations from both sides of the issue issued new releases stating their positions on the issues at the neighbouring World Health Organization.